Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn).

German pharmaceutical giant Merck has completed a €3 billion ($3. 5 billion) takeover of US biopharmaceutical company Springworks Therapeutics, the firm confirmed on Tuesday.

The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

Renee Gala joins a short list of female biopharma chief executives as she is set to take the reins at Jazz Pharmaceuticals, ...

The US president has given manufacturers as little as one year to relocate production back to the US or face 200% tariffs.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 billion ...

Merck KGaA, Darmstadt, Germany has closed the acquisition of SpringWorks Therapeutics Inc. for an enterprise value of $3.4 billion.

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion.